IDEXX Laboratories Enhances Veterinary Diagnostics with Integrated SDMA Testing

IDEXX Laboratories Enhances Veterinary Diagnostics with Integrated SDMA Testing

In a significant advancement for veterinary diagnostics, IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the integration of the SDMA renal biomarker into its Catalyst™ CLIPs. This development, effective from June 2026 in the United States and Canada, aims to provide veterinarians with earlier insights into kidney function, facilitating prompt and informed treatment decisions.

Seamless Integration for Enhanced Kidney Function Evaluation

The incorporation of SDMA into Catalyst CLIPs allows for a comprehensive kidney function assessment during routine chemistry panels. This integration ensures that veterinarians can evaluate kidney health without altering their existing workflows, thereby enhancing efficiency and diagnostic accuracy.

Supported by peer-reviewed studies, SDMA is recognized by the International Renal Interest Society (IRIS) as a key biomarker for evaluating kidney function in pets. Its inclusion in Catalyst CLIPs underscores IDEXX’s commitment to advancing veterinary diagnostics through innovative solutions.

Financial Performance and Market Response

As of July 17, 2026, IDEXX Laboratories’ stock (NASDAQ: IDXX) is trading at $567.44, reflecting a slight decrease of 0.58% from the previous close. The company’s market capitalization stands at approximately $45.49 billion, with a price-to-earnings (P/E) ratio of 41.75 and earnings per share (EPS) of $13.59.

In the first quarter of 2026, IDEXX reported revenues of $1.14 billion, surpassing analysts’ expectations of $1.11 billion. This strong performance led the company to raise its full-year profit and revenue outlook, now anticipating earnings per share between $14.45 and $14.90, up from the previous forecast of $14.29 to $14.80. Revenue projections have also been adjusted to a range of $4.68 billion to $4.76 billion, an increase from the prior range of $4.63 billion to $4.72 billion.

Strategic Innovations Driving Growth

IDEXX’s integration of SDMA into Catalyst CLIPs is part of a broader strategy to enhance diagnostic capabilities. In January 2026, the company expanded its IDEXX Cancer Dx™ Panel to include canine mast cell tumor detection, addressing over one-third of all canine cancer cases. Additionally, the rollout of FNA cytology on the IDEXX inVue Dx™ Cellular Analyzer in late 2025 has provided veterinarians with rapid, in-clinic diagnostic capabilities.

Conclusion

The integration of SDMA into Catalyst CLIPs represents a significant step forward in veterinary diagnostics, offering earlier detection of kidney function loss and enabling timely interventions. Coupled with strong financial performance and a commitment to innovation, IDEXX Laboratories continues to solidify its position as a leader in the veterinary diagnostics and animal health industry.